In today’s session Becton Dickinson and Co (BDX) registered an unusually high (62) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious BDX increase. With 62 contracts traded and 4824 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: BDX161216C00180000 closed last at: $0.45 or 50% up. About 247,481 shares traded hands. Becton Dickinson and Co (NYSE:BDX) has risen 6.74% since April 26, 2016 and is uptrending. It has outperformed by 1.48% the S&P500.
Analysts await Becton Dickinson and Co (NYSE:BDX) to report earnings on February, 1. They expect $2.12 earnings per share, up 8.16% or $0.16 from last year’s $1.96 per share. BDX’s profit will be $449.05M for 20.42 P/E if the $2.12 EPS becomes a reality. After $2.12 actual earnings per share reported by Becton Dickinson and Co for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
Becton Dickinson and Co (NYSE:BDX) Ratings Coverage
Out of 10 analysts covering Becton Dickinson (NYSE:BDX), 4 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 40% are positive. Becton Dickinson has been the topic of 16 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was initiated by Citigroup with “Neutral” on Thursday, November 12. The stock has “Buy” rating given by UBS on Friday, August 5. Citigroup maintained it with “Neutral” rating and $146 target price in Thursday, February 4 report. The stock of Becton Dickinson and Co (NYSE:BDX) earned “Buy” rating by Argus Research on Wednesday, August 19. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, January 4. The rating was maintained by Deutsche Bank with “Hold” on Monday, August 10. The company was upgraded on Thursday, February 11 by Deutsche Bank. RBC Capital Markets maintained Becton Dickinson and Co (NYSE:BDX) on Thursday, February 4 with “Sector Perform” rating. The firm has “Sell” rating given on Friday, September 23 by Citigroup. The stock has “Hold” rating given by Evercore on Wednesday, January 6.
According to Zacks Investment Research, “Becton, Dickinson and Co. is engaged principally in the manufacture and sale of a broad line of supplies, devices and systems used by health care professionals, medical research institutions and the general public. BD’s operations consist of three worldwide business segments: Medical Systems, Biosciences, and Preanalytical Solutions.”
Insitutional Activity: The institutional sentiment increased to 0.9 in 2016 Q2. Its up 0.01, from 0.89 in 2016Q1. The ratio increased, as 50 funds sold all Becton Dickinson and Co shares owned while 332 reduced positions. 63 funds bought stakes while 276 increased positions. They now own 178.24 million shares or 0.47% less from 179.07 million shares in 2016Q1.
Hugh Johnson Advsr Lc holds 1,413 shares or 0.09% of its portfolio. Reliance Tru Communication Of Delaware has invested 0.12% of its portfolio in Becton Dickinson and Co (NYSE:BDX). Moreover, Voya Inv Management Ltd Liability Company has 0.33% invested in Becton Dickinson and Co (NYSE:BDX) for 783,004 shares. Bartlett & Ltd accumulated 0% or 47 shares. The Pennsylvania-based Susquehanna Llp has invested 0% in Becton Dickinson and Co (NYSE:BDX). Voloridge Ltd last reported 25,407 shares in the company. Segall Bryant & Hamill Limited Company holds 0.02% of its portfolio in Becton Dickinson and Co (NYSE:BDX) for 5,482 shares. Moreover, Services Automobile Association has 0.08% invested in Becton Dickinson and Co (NYSE:BDX) for 132,054 shares. Veritable L P accumulated 12,239 shares or 0.05% of the stock. Thompson Davis And Co owns 44 shares or 0.01% of their US portfolio. Pacwest Fincl Mgmt Inc reported 11,460 shares or 1.21% of all its holdings. Tocqueville Asset Management Limited Partnership has 0.04% invested in the company for 18,265 shares. Lombard Odier And Cie (Canada) Partnership reported 1,400 shares or 0.83% of all its holdings. Tci Wealth Advisors has 1,206 shares for 0.11% of their US portfolio. Pennsylvania Tru accumulated 0.06% or 4,488 shares.
Insider Transactions: Since June 7, 2016, the stock had 0 insider purchases, and 5 insider sales for $10.28 million net activity. 1,931 shares with value of $328,019 were sold by Gallagher John E on Monday, June 13. $857,250 worth of Becton Dickinson and Co (NYSE:BDX) was sold by Shabshab Nabil. $2.07 million worth of Becton Dickinson and Co (NYSE:BDX) was sold by Tharby Linda M. 29,367 shares were sold by COHEN GARY M, worth $5.19M. $1.82 million worth of shares were sold by Sichak Stephen on Friday, November 4.
Becton, Dickinson and Company is a global medical technology firm engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company has a market cap of $36.67 billion. The Firm operates through two business divisions: BD Medical, which consists of Diabetes Care, Medication and Procedural Solutions, Medication Management Solutions, Pharmaceutical Systems and Respiratory Solutions business units, and BD Life Sciences, which consists of Preanalytical Systems, Diagnostic Systems and Biosciences business units. It has a 38.5 P/E ratio.
BDX Company Profile
Becton, Dickinson and Company (BD), incorporated in November 1906, is a global medical technology firm engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Firm operates through two business divisions: BD Medical and BD Life Sciences. The Firm sells its products outside the United States, including hypodermic needles and syringes; insulin syringes and pen needles; BD Hypak brand prefillable syringe systems; infusion therapy products, including Alaris infusion pumps; pharmacy automation equipment; respiratory equipment and disposable products; BD Vacutainer brand blood collection products; diagnostic systems and laboratory equipment and products, and flow cytometry instruments and reagents. The Firm has its manufacturing activities outside the United States in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Italy, Japan, Mexico, the Netherlands, Singapore, Spain and the United Kingdom.
More notable recent Becton Dickinson and Co (NYSE:BDX) news were published by: Prnewswire.com which released: “Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt …” on November 16, 2016, also Reuters.com with their article: “BRIEF-Becton, Dickinson and Co announces tender offers for outstanding deb…” published on November 16, 2016, Streetinsider.com published: “Form 4 BECTON DICKINSON & CO For: Nov 26 Filed by: Reidy Christopher R” on November 29, 2016. More interesting news about Becton Dickinson and Co (NYSE:BDX) were released by: Nasdaq.com and their article: “Becton, Dickinson and Company to boost quarterly dividend” published on November 12, 2016 as well as Seekingalpha.com‘s news article titled: “Becton, Dickinson & Co. (BDX) Q4 2016 Results – Earnings Call Transcript” with publication date: November 03, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.